Geode Capital Management LLC raised its position in shares of Hookipa Pharma Inc (NASDAQ:HOOK) by 108.0% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 339,130 shares of the company’s stock after buying an additional 176,051 shares during the quarter. Geode Capital Management LLC owned about 1.30% of Hookipa Pharma worth $4,561,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Citigroup Inc. raised its stake in Hookipa Pharma by 94.9% during the fourth quarter. Citigroup Inc. now owns 2,335 shares of the company’s stock valued at $26,000 after buying an additional 1,137 shares in the last quarter. American International Group Inc. raised its position in shares of Hookipa Pharma by 16.0% during the 1st quarter. American International Group Inc. now owns 8,379 shares of the company’s stock worth $113,000 after purchasing an additional 1,154 shares during the period. UBS Group AG raised its position in shares of Hookipa Pharma by 95.0% during the 1st quarter. UBS Group AG now owns 3,912 shares of the company’s stock worth $53,000 after purchasing an additional 1,906 shares during the period. JPMorgan Chase & Co. raised its position in shares of Hookipa Pharma by 10.4% during the 1st quarter. JPMorgan Chase & Co. now owns 37,447 shares of the company’s stock worth $504,000 after purchasing an additional 3,516 shares during the period. Finally, Bank of New York Mellon Corp raised its position in shares of Hookipa Pharma by 21.2% during the 4th quarter. Bank of New York Mellon Corp now owns 40,789 shares of the company’s stock worth $452,000 after purchasing an additional 7,144 shares during the period. Hedge funds and other institutional investors own 44.66% of the company’s stock.
Shares of HOOK stock opened at $7.92 on Thursday. Hookipa Pharma Inc has a 12-month low of $7.61 and a 12-month high of $20.00. The company has a market cap of $205.88 million, a price-to-earnings ratio of -4.40 and a beta of 1.14. The business has a 50 day simple moving average of $11.92. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.62 and a quick ratio of 7.62.
A number of brokerages have recently weighed in on HOOK. Zacks Investment Research upgraded Hookipa Pharma from a “hold” rating to a “buy” rating and set a $9.00 price target on the stock in a research report on Monday. SVB Leerink reiterated a “buy” rating on shares of Hookipa Pharma in a research report on Sunday, June 27th. HC Wainwright increased their price target on Hookipa Pharma from $16.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, May 13th. JMP Securities reissued a “buy” rating and issued a $25.00 price objective on shares of Hookipa Pharma in a report on Friday, June 4th. Finally, TheStreet lowered Hookipa Pharma from a “c-” rating to a “d” rating in a report on Wednesday, July 7th. Eight analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average price target of $20.25.
Hookipa Pharma Company Profile
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Want to see what other hedge funds are holding HOOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hookipa Pharma Inc (NASDAQ:HOOK).
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.